Latest News - Moderna
Top Corporates Hub
Moderna
mRNA Biotechs - Long-Term Value Risks Abound
28.08.2025 06:20
mRNA vaccine stocks face challenges post-pandemic. Discover why 'pick-and-shovel' biotech suppliers may offer better investment stability and growth.
Moderna’s updated Covid-19 vaccine gets Canadian approval
25.08.2025 12:10
The updated Covid-19 vaccine is approved for individuals six months and older.
Moderna to Present at Upcoming Conferences in September 2025
21.08.2025 11:00
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences: Morgan Stanley's 23rd Annual Global Healthcare Conference, on Monday, September 8th at ...
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead
13.08.2025 04:18
Over the past six months, Moderna’s shares (currently trading at $25.79) have posted a disappointing 19.2% loss, well below the S&P 500’s 5.4% gain. This may have investors wondering how to approach the situation.
The 5 Most Interesting Analyst Questions From Moderna’s Q2 Earnings Call
13.08.2025 04:15
Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in year-over-year sales and ongoing operational challenges. Management attributed quarterly performance primarily to lower COVID vaccine demand and highlighted that U.S. sales performed above internal expectations due to a stronger spring booster campaign. CEO Stéphane Bancel pointed to significant cost-cutting efforts, including a 35% reduction in combined cost of sales and SG
MRNA Q2 Deep Dive: Revenue Beat Overshadowed by Lower Guidance and Cost Cuts
13.08.2025 04:04
Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year on year to $142 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 10.5% below analysts’ estimates. Its non-GAAP loss of $2.13 per share was 29% above analysts’ consensus estimates.
mRNA Platform Strategic Business Analysis Report 2025 | Global Market to Reach $129.1 Billion by 2030 - Rising Infectious Diseases, Technological Advancements, and Pandemic Preparedness Drive Growth
11.08.2025 11:36
Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA Platform was estimated at US$152.0 Billion in 2024 and is projected to reach US$129.1 Billion by 2030, growing at a CAGR of -2.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.The mRNA platform has eme
The 3 Things That Matter for Moderna Now
11.08.2025 09:22
The company is still trying to prove that it isn't just a pandemic play.
RFK Jr’s mRNA funding halt signals “shift in US public health”
07.08.2025 11:34
The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.
AI is already upending the corporate org chart as it flattens the distance between the C-suite and everyone else
07.08.2025 08:31
AI isn't just a new tool for the modern workplace; it's quietly reshaping how companies are organized.
US Health Department Ending Federal mRNA Vaccine Development
06.08.2025 10:30
The US Health and Human Services Department said Tuesday it will soon end federal mRNA vaccine proje
Moderna Stock: Is Wall Street Bullish or Bearish?
06.08.2025 07:35
As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.
Moderna: RSV Upside Slim, Cash Burn Heavy
05.08.2025 11:06
Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read an analysis of MRNA stock now.
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034
05.08.2025 10:00
Growth in the Lipid Nanoparticles (LNPs) market is driven by increasing demand for mRNA-based therapeutics and advances in delivery systems. LNPs, vital in protecting and delivering mRNA molecules, expand beyond infectious diseases into cancer immunotherapy and genetic therapies. The U.S. leads in this market with strong biotech roots. Key players, including Moderna and BioNTech, invest in R&D and partnerships to enhance LNP applications. The therapeutics segment holds significant market share,
What Moved Markets This Week
02.08.2025 07:42
Wall Street faced its worst week since May amid weak jobs data, trade tensions, and a hawkish Federal Reserve.
Nvidia, eBay, Moderna: Trending Tickers
31.07.2025 15:06
Nvidia (NVDA) is in focus after Chinese regulators flagged security concerns in its H20 AI chips. eBay (EBAY) stock is jumping after the company issued a strong sales forecast, driven by increased demand for used and refurbished goods. Moderna (MRNA) is cutting 10% of its global workforce as it reins in costs amid falling COVID-19 vaccine sales. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
Moderna to lay off 10% of workforce in ‘difficult but necessary step’
31.07.2025 11:27
In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the “realities of our business.”
Moderna Cuts 10% of Its Staff as Cash Hoard Dwindles
31.07.2025 11:15
The layoffs come as Moderna’s cash position has raised worries on Wall Street that the company may need to raise new capital.
Moderna Earnings: What To Look For From MRNA
31.07.2025 03:00
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before the bell. Here’s what to expect.
Daily Dividends From Option ETFs
28.07.2025 08:00
New weekly-paying option ETFs let income investors earn dividends daily, but come with big risks and unknowns. See why careful use is key in a diversified portfolio.